Nevertheless, as already discussed above, it has become evident that genetic ablation of TGF-β signaling pathway components in selected immune cell types (e.g., CD4+ and CD8+ T cells, NK cells, or dendritic cells) can re-activate the anti-tumor response in different cancer pre-clinical models. This evidence concerns the gene TGFB1 and cancer.